1. Home
  2. CHD vs BIIB Comparison

CHD vs BIIB Comparison

Compare CHD & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Church & Dwight Company Inc.

CHD

Church & Dwight Company Inc.

HOLD

Current Price

$97.70

Market Cap

23.4B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$201.23

Market Cap

27.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHD
BIIB
Founded
1846
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.4B
27.3B
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
CHD
BIIB
Price
$97.70
$201.23
Analyst Decision
Buy
Buy
Analyst Count
17
25
Target Price
$102.18
$206.83
AVG Volume (30 Days)
1.7M
1.3M
Earning Date
05-01-2026
04-29-2026
Dividend Yield
1.28%
N/A
EPS Growth
27.43
N/A
EPS
0.91
2.15
Revenue
$6,203,200,000.00
$9,890,600,000.00
Revenue This Year
$0.25
N/A
Revenue Next Year
$3.65
N/A
P/E Ratio
$107.28
$94.90
Revenue Growth
1.57
2.22
52 Week Low
$81.33
$123.38
52 Week High
$106.04
$219.72

Technical Indicators

Market Signals
Indicator
CHD
BIIB
Relative Strength Index (RSI) 51.83 49.95
Support Level $91.85 $186.30
Resistance Level $100.48 $202.91
Average True Range (ATR) 1.98 8.68
MACD 0.01 -0.85
Stochastic Oscillator 51.13 48.87

Price Performance

Historical Comparison
CHD
BIIB

About CHD Church & Dwight Company Inc.

Church & Dwight is the leading global producer of baking soda. Its portfolio extends beyond its legacy category to include laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its brands also include Batiste, OxiClean, Vitafusion, Hero, and TheraBreath, which, together with Arm & Hammer, account for around 70% of its annual sales and profits. Most recently, the firm added Touchland and its hand sanitizer business to its fold. Even as it works to expand its product reach, Church & Dwight still derives around 80% of its sales from its home market in the US.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: